EPM’s Medicine Revolution

Medicine to All

Novel therapeutics from synthetic cannabinoid acids for a healthier and brighter future

Novel therapeutics from synthetic cannabinoid acids for a healthier and brighter future
Our Story

Patient-focused Pharmaceutical Group

EPM is developing prescription medicine based on novel discoveries of synthetic cannabinoid acids to address unmet patient needs. These innovations represent new treatment options and aim at alleviating a wide range of therapeutic conditions for millions of patients worldwide.

Previous
Maria, 32
Maria, 32
Maria, 32
Maria, 32
My diagnosis made me miserable. But the promise of EPM’s effective solution gave me hope for a better future.
Maria, 32
Crohn's Disease
Linda, 45
Linda, 45
Linda, 45
Linda, 45
I’ve been living with my Colitis for over 6 years, EPM’s discovery can be a real life-changer.
Linda, 45
Ulcerative Colitis
Prof. Raphael Mechoulam
Prof. Raphael Mechoulam
Prof. Raphael Mechoulam
Prof. Raphael Mechoulam
Cannabinoid acids are compounds that are much more potent than cannabinoids and have an outstanding therapeutic potential.
Prof. Raphael Mechoulam
Head of Chemistry Discovery
Next
Our Treatments

Curing and Treating Patients Worldwide

EPM is developing cannabinoid acid-based therapeutic solutions providing alternative treatments for patients. This is the driving force behind EPM’s research program, which is based on 14 IP protected APIs. Currently EPM’s focus is on two main therapeutic conditions: Metabolic and skin disorders.